IRIS
Fiorino, Gionata
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.482
AS - Asia 6.179
EU - Europa 2.487
SA - Sud America 1.478
AF - Africa 360
Continente sconosciuto - Info sul continente non disponibili 271
OC - Oceania 25
Totale 23.282
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.177
SG - Singapore 3.683
BR - Brasile 1.193
CN - Cina 965
VN - Vietnam 761
IT - Italia 659
FI - Finlandia 413
IE - Irlanda 277
DE - Germania 221
NG - Nigeria 221
GB - Regno Unito 190
FR - Francia 183
CA - Canada 177
HK - Hong Kong 146
NL - Olanda 113
IN - India 112
AR - Argentina 104
SE - Svezia 104
BD - Bangladesh 71
TR - Turchia 67
RU - Federazione Russa 59
MX - Messico 57
IQ - Iraq 54
EC - Ecuador 51
ID - Indonesia 48
ES - Italia 43
IL - Israele 43
UA - Ucraina 42
CO - Colombia 39
ZA - Sudafrica 38
BE - Belgio 37
JP - Giappone 32
EG - Egitto 26
CL - Cile 24
PY - Paraguay 24
PL - Polonia 22
SA - Arabia Saudita 22
DZ - Algeria 21
PK - Pakistan 21
VE - Venezuela 21
AU - Australia 20
CZ - Repubblica Ceca 20
CR - Costa Rica 14
JM - Giamaica 14
KZ - Kazakistan 14
MA - Marocco 14
PH - Filippine 14
UZ - Uzbekistan 14
IR - Iran 13
KE - Kenya 13
LT - Lituania 13
AE - Emirati Arabi Uniti 12
RO - Romania 12
KR - Corea 11
MY - Malesia 11
PE - Perù 11
PT - Portogallo 11
AZ - Azerbaigian 10
NP - Nepal 9
AL - Albania 8
HN - Honduras 8
SK - Slovacchia (Repubblica Slovacca) 8
TN - Tunisia 8
UY - Uruguay 8
AT - Austria 6
DO - Repubblica Dominicana 6
GR - Grecia 6
NI - Nicaragua 6
BB - Barbados 5
EE - Estonia 5
GT - Guatemala 5
JO - Giordania 5
MD - Moldavia 5
QA - Qatar 5
SV - El Salvador 5
SY - Repubblica araba siriana 5
A2 - ???statistics.table.value.countryCode.A2??? 4
BA - Bosnia-Erzegovina 4
BY - Bielorussia 4
CH - Svizzera 4
GE - Georgia 4
NO - Norvegia 4
SN - Senegal 4
BN - Brunei Darussalam 3
ET - Etiopia 3
EU - Europa 3
KH - Cambogia 3
KW - Kuwait 3
NZ - Nuova Zelanda 3
OM - Oman 3
PR - Porto Rico 3
PS - Palestinian Territory 3
AM - Armenia 2
BF - Burkina Faso 2
BO - Bolivia 2
BW - Botswana 2
CI - Costa d'Avorio 2
CY - Cipro 2
GA - Gabon 2
HR - Croazia 2
Totale 22.986
Salva come PNG Salva come JPEG
Città #
Singapore 1.733
Wilmington 1.555
Chandler 1.238
Ashburn 641
The Dalles 601
San Mateo 587
Dallas 532
Ann Arbor 435
Shanghai 426
San Jose 418
Helsinki 410
Council Bluffs 323
Princeton 296
Leawood 286
Lawrence 273
Ho Chi Minh City 272
Milan 271
Dublin 270
New York 244
Boardman 234
Benin City 220
Beijing 216
Hanoi 170
Fairfield 154
Woodbridge 154
Paris 148
Hong Kong 140
Santa Clara 137
Los Angeles 115
São Paulo 114
Rome 109
Toronto 96
Amsterdam 92
Phoenix 92
London 75
Buffalo 73
Rio de Janeiro 54
Norwalk 51
Seattle 51
Columbus 44
Houston 41
Orem 41
Kocaeli 40
Chicago 39
Haiphong 36
San Diego 35
Brussels 33
Brasília 28
Monmouth Junction 28
Brooklyn 27
Atlanta 26
Miami 26
Redwood City 26
Da Nang 24
Baghdad 21
Curitiba 21
Frankfurt am Main 21
Guayaquil 21
Munich 20
Naples 20
Philadelphia 20
Montreal 19
Belo Horizonte 18
Chennai 18
Figino 18
Johannesburg 18
Tokyo 18
Biên Hòa 17
Bologna 17
Cambridge 17
Campinas 17
Pune 17
Abbiategrasso 16
Charlotte 16
Turin 16
Falkenstein 15
Las Vegas 15
Porto Alegre 15
Brno 14
Hải Dương 14
Sacramento 14
The Bronx 14
Warsaw 14
Boston 13
Cairo 13
Nairobi 13
Ninh Bình 13
Riverside 13
Abbeville 12
Birmingham 12
Erbil 12
Guarulhos 12
Manchester 12
Medellín 12
Mexico City 12
Can Tho 11
Cincinnati 11
Cleveland 11
Des Moines 11
Dhaka 11
Totale 14.505
Salva come PNG Salva come JPEG
Nome #
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications 401
Adalimumab in ulcerative colitis: hypes and hopes 158
A Prospective Comparison Between Computerized Tomography (CT) and Magnetic Resonance (MR) in Ileo-Colonic Crohn's Disease: A Single-Center Experience. 156
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX®) for active, mild-to-moderate ulcerative colitis 141
Bowel damage as assessed by the Lémann Index is reversible on anti-TNF therapy for Crohn's disease 140
New Drug Delivery Systems in Inflammatory Bowel Disease: MMX (TM) and Tailored Delivery to the Gut 140
Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease 140
A Prospective Comparison Between 1.5t Magnetic Resonance and 3t Magnetic Resonance in Ileo-Colonic Crohn's Disease: A Single Center Experience 136
Adalimumab in Crohn's disease : tips and tricks after 5 years of clinical experience 135
ECCO-ESGAR Guideline for Diagnostic Assessment in Inflammatory Bowel Disease Part 2. IBD scores and general principles and technical aspects 134
Narrow-band imaging endoscopy to assess mucosal angiogenesis in inflammatory bowel disease: a pilot study 133
Adalimumab is effective in achieving clinical and endoscopic long-term deep remission : a case report 128
Risk of postoperative recurrence and postoperative management of Crohn's disease 127
Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease 127
Perception of reproductive health in women with inflammatory bowel disease 124
A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies 122
Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome. 121
Second-Generation Corticosteroids for the Treatment of Crohn's Disease and Ulcerative Colitis: More Effective and Less Side Effects? 120
A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis 118
PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD 117
Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study 115
MFSD2A Promotes Endothelial Generation of Inflammation-resolving Lipid Mediators and Reduces Colitis in Mice 115
Accuracy of a New Fujiifilm Blue Light Prototype in Predicting the Histology of Subcentimetric Polyps 115
Emerging biologics in the treatment of inflammatory bowel disease : what is around the corner? 113
Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease : a prospective study 113
Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign 111
‘Quality of care’ standards in inflammatory bowel disease: A systematic review 111
Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study 110
A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMX® for mild-to-moderate ulcerative colitis 110
Balanced Propofol Sedation (BPS) Administered by Non-Anesthesiologists vs Midazolam Alone for Endoscopic Procedure in Patients With IBD: A Single Center Open-Label Trial 109
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment 108
Impact of Medications on Radiologic Disease Activity and Bowel Damage in Crohn's Disease: A Prospective Longitudinal MRI Study 107
Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease 107
Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease 107
A PROSPECTIVE MULTICENTER OBSERVATIONAL COHORT STUDY ASSESSING THE EFFECTIVENESS OF BUDESONIDE MMX® FOR MILD-TO-MODERATE ULCERATIVE COLITIS 107
Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease 107
Effect of tumour necrosis factor antagonists on avoiding surgery in stricturing Crohn's disease: a tertiary centre real-life experience 105
Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn's disease : a case-matched analysis 105
Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy 104
Effect of Immunosuppression on Immune Response to Pneumococcal Vaccine in Inflammatory Bowel Disease: A Prospective Study 104
Impact of Tumour Necrosis Factor Antagonists on Avoiding Surgery in Stricturing Crohn's Disease: A Tertiary Center Real-Life Experience 103
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting 103
Interstitial and granulomatous lung disease in inflammatory bowel disease patients 103
Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease 102
A PROLONGED FOLLOW-UP ON THE EFFICACY AND SAFETY OF INFLIXIMAB BIOSIMILAR CT-P13 IN IBD ACROSS ITALY: THE PROSIT COHORT 101
Are Surgical Rates Decreasing in the Biological Era In IBD? 101
Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients 100
Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis 100
Review article: anti-fibrotic agents for the treatment of Crohn's disease - lessons learnt from other diseases 100
The bacterial sensor Triggering Receptor Expressed on Myeloid cells 2 (TREM-2) is a crucial pathogenic mediator in inflammatory bowel disease (IBD) 98
The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes 97
Comparison between 1.5 and 3.0 Tesla magnetic resonance enterography for the assessment of disease activity and complications in ileo-colonic Crohn's disease 96
The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges 96
Regulatory T-Cell Therapy for Crohn's Disease: In Vivo Veritas 95
Adalimumab for the treatment of pediatric Crohn's disease 95
OP018 High-fat diet and inflammation drive intestinal fibrosis enhancing epithelial–mesenchymal transition through the activation of S1P3 signalling 95
Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease A Systematic Review and Meta-Analysis of Randomized Controlled Trials 94
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 94
Anemia in Inflammatory Bowel Disease: The Opening of Pandora's Box? 93
Contrast-enhancement at magnetic resonance enterography does not differentiate between fibrosis and inflammation in Crohn's disease: a prospective cohort study 93
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management 93
Review article: infliximab for Crohn's disease treatment - shifting therapeutic strategies after 10 years of clinical experience 93
Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan 93
Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study 92
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naive Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study 92
Adalimumab and Azathioprine Combination Therapy for Crohn's Disease: A Shining Diamond? 91
Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients 91
Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease 91
The Role of Magnetic Resonance Imaging in Detecting Intestinal Fibrosis in Crohn's Disease 91
STIMULATION OF CYP450-MEDIATED omega-3 DOCOSAHEXAENOIC ACID (DHA) METABOLISM VIA MFSD2A AS A NOVEL THERAPY FOR INFLAMMATORY BOWEL DISEASE 90
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 90
Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation 89
Familial aggregation in inflammatory bowel disease: Is it genes or environment? 89
Clinician Education and Adoption of Preventive Measures for COVID-19: A Survey of a Convenience Sample of General Practitioners in Lombardy, Italy 89
Dose Optimization Is Effective in Patients With Ulcerative Colitis Losing Response to Infliximab: A Collaborative Multicentre Retrospective Study 88
Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation 88
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target 88
The safety of biological pharmacotherapy for the treatment of ulcerative colitis 88
Clinical Utility of the LeMann Index and Rutgeerts Score to Predict Postoperative Course of Crohn's Disease: A Retrospective Single-Center Cohort Study 88
Emerging therapeutic targets and strategies in Crohn's disease 87
Videocapsule endoscopy in portal hypertension: Seek till you find 87
VAGUS NERVE STIMULATION REDUCES DISEASE ACTIVITY AND MODULATES SERUM AND AUTONOMIC BIOMARKERS IN BIOLOGICREFRACTORY CROHN'S DISEASE 87
Commentary: associations between immune activation, intestinal permeability and irritable bowel syndrome 86
MRI in Crohn's disease : current and future clinical applications 86
Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine? 86
JAK inhibitors: Novel developments in management of ulcerative colitis 86
Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials 86
H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biologics 86
A HEALTH TECHNOLOGY-RELATED COST DESCRIPTION CONCERNING ITALIAN IBD CENTRES DEALING WITH CROHN'S DISEASE: RESULTS FROM SOLE STUDY 86
Comparison of two methods for the in-vivo diagnosis of Helicobacter pylori infection using a tablet of C-13-urea 86
Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients 85
Capsule Endoscopy in Crohn's Disease 85
Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease 84
ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment 84
MRE Findings at Crohn's Disease Diagnosis: Disease Activity, Bowel Damage and Predictive Value for Long-Term Outcomes 84
Infliximab Inhibits Mucosal Pathological Angiogenesis in Crohn's Disease 84
y ANTIBODIES TO INFLIXIMAB IN PATIENTS TREATED WITH EITHER THE REFERENCE BIOLOGIC OR THE BIOSIMILAR CT-P13 SHOW IDENTICAL REACTIVITY TOWARDS BIOSIMILARS CT-P13 AND SB2 IN INFLAMMATORY BOWEL DISEASE 84
Heat shock protein 47 is a new candidate molecule as anti-fibrotic treatment of Crohn's disease: authors' reply 83
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission 83
Quality of care standards in inflammatory bowel diseases: a European Crohn's and Colitis Organisation (ECCO) position paper 83
Totale 10.562
Salva come PNG Salva come JPEG
Categoria #
all - tutte 155.601
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 155.601
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.329 0 0 0 304 12 8 64 196 152 203 308 82
2022/20233.327 612 152 386 349 205 279 16 253 541 321 168 45
2023/20241.918 202 148 382 92 56 252 101 117 34 41 167 326
2024/20252.695 60 61 25 55 29 323 127 300 349 738 294 334
2025/20268.040 1.036 547 720 1.032 286 249 1.946 440 406 448 266 664
2026/20272.818 727 617 1.150 324 0 0 0 0 0 0 0 0
Totale 23.282